A pharmacokinetic (PK) study in patients with impaired hepatic function should be conducted in the following situations:

  • If hepatic metabolism and/or excretion accounts for substantial portion ( >20 percent of the absorbed drug) of the elimination of a parent drug or active metabolite;
  • In the case of a narrow therapeutic range drug, and;
  • If metabolism of the drug is unknown.

The design and conduct of these hepatic impairment (HI) studies may have evolved since the latest version of the relevant guidance document from the FDA (2003).


Access the Poster Here

Nous contacter
Appeler notre équipe 

Téléphone : 1 919 876-9300
Télécopie : +1 919 876 9360
Sans frais : +1 866 462 7373


Ingrid Freije, Fadi Achkar, Mario Tanguay
Syneos Health Clinique, QC, Canada
Faculty of Pharmacy, Université de Montréal, QC, Canada

Powered by Translations.com GlobalLink OneLink Software